Search results for "PROPHYLAXIS"

showing 10 items of 175 documents

Secondary prophylaxis vs. on-demand treatment to improve quality of life in severe adult haemophilia A patients: a prospective study in a single cent…

2013

Background Retrospective publications show a decrease in the bleeding frequency and an improvement in the quality of life (QoL) in severe adult haemophilia A (SAHA) after switching from the on-demand treatment (DT) to secondary prophylaxis (SP). But there are no prospective studies which demonstrate, using a haemophilia-specific questionnaire, an improvement in the QoL after such treatment change. The main objective of this study is to prospectively compare the QoL and the musculoskeletal assessment after switching from DT to SP in SAHA using the A36 Hemofilia-QoL®. As secondary objective, we compare the haemarthrosis frequency and factor VIII consumption in DT and SP during a similar perio…

AdultMalePediatricsmedicine.medical_specialtyHaemophilia Ahaemophilia AHemorrhageHemophilia AQuality of lifeSurveys and QuestionnairesHemarthrosismedicineHumansProspective StudiesProspective cohort studyRetrospective StudiesmusculoskeletalFactor VIIIbusiness.industrySecondary prophylaxisHematologyGeneral MedicineMiddle Agedmedicine.diseasehumanitiesbleeding incidenceSingle centreOn demand treatmentquality of lifesecondary prophylaxisQuality of LifeFemalebusinessVox sanguinis
researchProduct

Alteration of vancomycin pharmacokinetics during cardiopulmonary bypass in patients undergoing cardiac surgery.

2003

The alteration of vancomycin pharmacokinetics during cardiopulmonary bypass (CPB) in patients undergoing cardiac surgery was studied. Eighteen patients were enrolled in the study. Vancomycin (1 g) was intravenously infused one to two hours before surgery. Blood samples were taken before, during, and after CPB. Serum drug concentrations were determined by an automated fluorescence polarization immunoassay and adjusted, with a bayesian analysis, to a bi-compartmental model implemented in a pharmacokinetic system program. Serum creatinine, hematocrit, and plasma proteins were also measured before, during, and after CPB. During CPB, serum creatinine, hematocrit, and plasma protein values all de…

AdultMaleTime FactorsHematocritlaw.inventionchemistry.chemical_compoundPharmacokineticslawVancomycinBlood plasmaCardiopulmonary bypassMedicineHumansInfusions IntravenousAgedMonitoring PhysiologicPharmacologyVolume of distributionCreatinineCardiopulmonary Bypassmedicine.diagnostic_testbusiness.industryHealth PolicyAntibiotic ProphylaxisMiddle AgedBlood proteinsAnti-Bacterial Agentssurgical procedures operativechemistryAnesthesiaVancomycinFemalebusinesscirculatory and respiratory physiologymedicine.drugHalf-LifeAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
researchProduct

Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-contro…

2019

Introduction Non-invasive vagus nerve stimulation (nVNS; gammaCore®) has the potential to prevent migraine days in patients with migraine on the basis of mechanistic rationale and pilot clinical data. Methods This multicentre study included a 4-week run-in period, a 12-week double-blind period of randomised treatment with nVNS or sham, and a 24-week open-label period of nVNS. Patients were to administer two 120-second stimulations bilaterally to the neck three times daily (6–8 hours apart). Results Of 477 enrolled patients, 332 comprised the intent-to-treat (ITT) population. Mean reductions in migraine days per month (primary outcome) were 2.26 for nVNS (n = 165; baseline, 7.9 days) and 1.8…

AdultMaleVagus Nerve StimulationMigraine DisordersMigraine prophylaxismedicine.medical_treatmentMedizinlaw.inventionDouble blindvagal activation03 medical and health sciences0302 clinical medicineDouble-Blind MethodEpisodic migraineRandomized controlled triallawHumanspreventive therapyMedicineIn patient030304 developmental biologymigraine prophylaxis0303 health sciencesNeuromodulationbusiness.industryNon invasiveNon-pharmacologic treatmentOriginal ArticlesGeneral MedicineMiddle Agedmedicine.diseaseNeuromodulation (medicine)3. Good healthTreatment OutcomeMigrainenon-pharmacologic treatmentAnesthesiaVagal activationFemaleNeurology (clinical)Preventive therapybusinessRCT030217 neurology & neurosurgeryVagus nerve stimulationCephalalgia
researchProduct

Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A

2018

Introduction: Personalised pharmacokinetics (PK) using Bayesian analysis with limited sampling is assumed to help to optimise prophylaxis in haemophilia A (HA) patients. Materials and methods: Our prospective, observational study analysed the influence of PK parameters on clinical variables (bleeding rates, joint status, adherence, and consumption) using myPKFiT (R) in a cohort of twenty-one severe and moderate HA patients on prophylaxis with recombinant FVIII (Advate (R)) in two periods of one year, the first before PK-based tailoring and the second after PK-guided prophylaxis. Intra-individual and inter-individual coefficients of variation (CV) of half-life (t(1/2)) were calculated. Resul…

AdultMalemedicine.medical_specialtyAdolescentHaemophilia AModerate haemophilia A030204 cardiovascular system & hematologyHemophilia ARecombinant factor viiiRecombinant factor VIIIYoung Adult03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineHaemophilia AArthropathymedicineLimited samplingHumansPharmacokineticsProspective StudiesAgedFactor VIIIbusiness.industryBayes TheoremHematologyBayesian estimationMiddle Agedmedicine.diseasePK-guided prophylaxis030220 oncology & carcinogenesisCohortFemaleObservational studybusinessmyPKFiTThrombosis Research
researchProduct

Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series

2020

BAY 81-8973 is an unmodified, full-length third generation recombinant factor VIII (rFVIII) which offers a more favorable pharmacokinetic (PK) profile, compared to its predecessor sucrose-formulated rFVIII (rFVIII-FS). We here report on a retrospective case series of nine patients affected by hemophilia A (HA), with variable disease severity, bleeding phenotype and comorbidities, to underline our clinical practice on prophylaxis with a recently introduced standard hall-life recombinant Factor VIII. The current case series highlights how the current clinical management of hemophilia is able to personalize treatment in several specific conditions like concomitant illnesses with thrombotic ris…

AdultMalemedicine.medical_specialtyAdolescentHemophilia A HemarthrosisHemophilic arthropathyrFVIIIPharmacokineticProphylaxisHaemophilia A030204 cardiovascular system & hematologyHemophilia ARecombinant factor viii03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineMedicineHumansChildVariable disease severityAgedRetrospective StudiesThrombotic riskFactor VIIIbusiness.industryHematologyHemarthrosisMiddle Agedmedicine.diseaseThird generationClinical PracticeTreatment OutcomeConcomitantbusiness030215 immunology
researchProduct

Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis

2021

The primary aim of this study was to describe the use of primary anti-infective prophylaxis (AP) in common clinical practice in patients affected by immune thrombocytopenia (ITP) and treated with RTX. Population studied consisted of patients affected by ITP (age ≥ 18 years) who had received at least one dose of RTX from January 2008 to June 2018. Five Italian haematology centres participated in the current study. Data were retrospectively collected: demographic data (age, gender), concomitant comorbidities and previous therapies for ITP, characteristics of AP, the occurrence of infections and their management. The ITP cohort consisted of 67 patients sub-grouped into two categories according…

AdultMalemedicine.medical_specialtyAdolescentPopulationOpportunistic InfectionsPneumocystis pneumoniaYoung Adult03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansPractice Patterns Physicians'educationAgedRetrospective StudiesAged 80 and overPurpura Thrombocytopenic Idiopathiceducation.field_of_studyHematologybusiness.industrySulfamethoxazoleHematologyGeneral MedicineAntibiotic ProphylaxisMiddle Agedmedicine.diseaseTrimethoprimItaly030220 oncology & carcinogenesisConcomitantCohortFemaleRituximabImmune thrombocytopenia . Rituximab . Antimicrobial prophylaxis . InfectionsRituximabbusiness030215 immunologymedicine.drugAnnals of Hematology
researchProduct

Perioperative antibiotic prophylaxis in plastic surgery: A prospective study of 1100 adult patients.

2011

Summary Background Although guidelines for antibiotic prophylaxis to prevent surgical site infections (SSIs) exist, specific guidelines for plastic surgery are missing and there is a tendency towards excessive administration of antibiotics. A total of 1100 patients were prospectively studied according to an evidence-based protocol to investigate if limiting antibiotic prophylaxis to high-risk cases does increase the infection rate. Methods Between April 2009 and April 2010, 1100 consecutive patients undergoing elective reconstructive or cosmetic procedures were enrolled. Procedures were classified into four groups, and prophylactic antibiotics were only administered perioperatively in 23.4%…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentAntibioticsSettore MED/19 - Chirurgia PlasticaRhinoplastyAntibiotic prophylaxiHumansSurgical Wound InfectionMedicineProspective StudiesAntibiotic prophylaxisProspective cohort studyAgedAged 80 and overChi-Square DistributionEvidence-Based Medicinebusiness.industryGenitourinary systemIncidenceIncidence (epidemiology)Antibiotic ProphylaxisLength of StayMiddle AgedPlastic Surgery ProceduresMicrosurgerySurgical site infection (SSI)SurgeryPlastic surgeryLogistic ModelsTreatment OutcomeSSI preventionItalyPractice Guidelines as TopicFemaleSurgerybusinessInfections in plastic surgery
researchProduct

Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): a matched-pair study comparing oral fl…

2005

The safety and efficacy of early bacterial prophylaxis with piperacillin-tazobactam were prospectively evaluated in 51 autologous peripheral blood stem cell transplantation (PBSCT) recipients. The results were compared with those obtained in 51 control patients receiving oral fluoroquinolones in a retrospective matched-pair control study. Overall, 76% of the study group and 98% of the control group developed at least one febrile episode during neutropenia (P=0.002). Time from neutropenia to the first febrile episode (FFE) was significantly longer in the study group than in the control group (P=0.04). Once a febrile episode appeared, the duration of fever was significantly longer in cases th…

AdultMalemedicine.medical_specialtyNeutropeniaAdolescentFevermedicine.drug_classMatched-Pair AnalysisPremedicationAntibioticsPenicillanic AcidBacteremiaGram-Positive BacteriaTazobactamTransplantation AutologousInternal medicineAmphotericin BGram-Negative Bacteriapolycyclic compoundsmedicineHumansAntibacterial agentAgedPiperacillinTransplantationPeripheral Blood Stem Cell TransplantationHematologybusiness.industryHematologyBacterial InfectionsMiddle AgedSurgeryPiperacillin Tazobactam Drug CombinationPiperacillin/tazobactamChemoprophylaxisFemaleStem cellbusinessPiperacillinmedicine.drugFluoroquinolonesBone marrow transplantation
researchProduct

Efficacy and safety comparison of two amoxicillin administration schedules after third molar removal. A randomized, double-blind and controlled clini…

2009

Objective: The aim of this comparative double-blind, prospective, randomized, clinical trial was to evaluate two amoxicillin administration patterns. The first was a short prophylactic therapy and the second a long postoperative regimen. Study Design: The study population consisted of 160 patients who underwent mandibular third molar extraction. Patients were randomized into two equal groups. In group 1, 2 grams of amoxicillin were administered 1 hour before the procedure and 1 gram 6 hours after surgery. In group 2, patients received 1 gram of amoxicillin 6 hours after surgery followed by 1 gram every 8 hour for 4 days. All patients received the same number of tablets thanks to the use of …

AdultMalemedicine.medical_specialtyPlaceboDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawmedicineHumansProspective StudiesAntibiotic prophylaxisProspective cohort studyGeneral DentistryPostoperative Carebusiness.industryAmoxicillinPain scaleAmoxicillinAntibiotic Prophylaxis:CIENCIAS MÉDICAS [UNESCO]MolarSurgeryAnti-Bacterial AgentsClinical trialRegimenOtorhinolaryngologyAnesthesiaUNESCO::CIENCIAS MÉDICASTooth ExtractionSurgeryFemalebusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice

2015

Producción Científica

AdultMalemedicine.medical_specialtyRiñones - TrasplanteCongenital cytomegalovirus infectionCytomegaloviruskidney transplantationSIDA (Enfermedad)Kaplan-Meier EstimateDiseaseAntiviral AgentsAsymptomaticRisk FactorsInternal medicineseropositive recipientpreemptive therapymedicineHumansValganciclovirProspective StudiesRenal InsufficiencyPropensity ScoreGanciclovircytomegalovirusKidney transplantationAgedProportional Hazards ModelsTransplantation3205.06 Nefrologíabusiness.industryProportional hazards modelIncidenceIncidence (epidemiology)antiviral prophylaxisMiddle Agedmedicine.diseaseKidney TransplantationDiscontinuationSurgerymulticenter studySpainCytomegalovirus InfectionsPropensity score matchingFemalemedicine.symptombusinessImmunosuppressive AgentsGlomerular Filtration Rate
researchProduct